Accès ouvert · CC BY

[123I]-metaiodobenzylguanidine imaging findings and outcome in patients with metastatic neuroblastoma

Article scientifique 2022 Sciences de la santé Anglais

Résumé

Background: 123I-Metaiodobenzylguanidine ([123I]mIBG) is the agent of choice to assess for presence of metastases and therapy response in patients with neuroblastoma.Aim: To assess [123I]mIBG scan results and outcome in patients with stage 4 neuroblastoma at our institution.Setting: Red Cross War Memorial Children’s Hospital.Methods: A retrospective review of baseline and follow-up [123I]mIBG scans of patients who presented between January 2001 and May 2015. The clinical follow up extended until October 2019. The association between the baseline and post-induction Curie score (CS) and overall survival (OS) were assessed.Results: Thirty-four patients with stage 4 disease were included. Twenty-two (65%) patients died. The median age at diagnosis for survivors was 15.5 months vs 39 months for those who died (Kruskal Wallis c2 = 4.63, p = 0.03). Neither the baseline CS nor the post-induction CS predict the outcome or duration of survival. The median OS for a baseline CS ≤ 12 and CS 12 was 19 and 26 months, p = 0.13. The median OS for a post-induction CS 2 and CS ≤ 2 was 28 and 26 months, p = 0.66.Conclusion: In this study, baseline, post-induction and reduction in CS did not predict OS in stage 4 neuroblastoma. Factors such as small patient numbers, less intensive treatment regimes, and possible poorly dedifferentiated disease have been identified for this finding.Contribution: In contrast to international studies the Curie score did not predict treatment outcome in the South African setting where the vast majority of patients are treated with OPEC/OJEC OPEC/OJEC (vincristine [O], cisplatin [P], etoposide [E], cyclophosphamide [C] and carboplatin [J]) chemotherapy.

Citer ce document

Amoako, Y. A., Eyssen, A. V., & Brink, A. (2022). [123I]-metaiodobenzylguanidine imaging findings and outcome in patients with metastatic neuroblastoma. South African Journal of Oncology. https://doi.org/10.4102/sajo.v7i0.250

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 10/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations (hors robots) : 18

Téléchargements (hors robots) : 0

Méthode de comptage